Published in J Immunol on July 01, 2010
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet (2011) 4.19
Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol (2011) 2.07
Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med (2013) 1.91
A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun (2014) 1.64
Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification. Am J Respir Crit Care Med (2015) 1.42
Crystal structures of the kinase domain of the sulfate-activating complex in Mycobacterium tuberculosis. PLoS One (2015) 1.39
Latent tuberculosis: what the host "sees"? Immunol Res (2011) 1.35
Multiscale computational modeling reveals a critical role for TNF-α receptor 1 dynamics in tuberculosis granuloma formation. J Immunol (2011) 1.32
Mycobacterium tuberculosis Eis protein initiates suppression of host immune responses by acetylation of DUSP16/MKP-7. Proc Natl Acad Sci U S A (2012) 1.30
Comparative miRNA expression profiles in individuals with latent and active tuberculosis. PLoS One (2011) 1.25
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett (2013) 1.25
Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. Pulm Med (2012) 1.24
Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog (2015) 1.21
Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today (2011) 1.21
The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol (2013) 1.15
The regulation of sulfur metabolism in Mycobacterium tuberculosis. PLoS Pathog (2011) 1.15
The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci (2014) 1.12
Multi-scale modeling predicts a balance of tumor necrosis factor-α and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection. PLoS One (2013) 1.11
Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun (2014) 1.08
Mycobacterium marinum causes a latent infection that can be reactivated by gamma irradiation in adult zebrafish. PLoS Pathog (2012) 1.07
Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol (2012) 1.07
Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS One (2013) 1.04
The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect (2011) 1.01
Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice. Am J Pathol (2014) 0.99
Toward a unified biosignature for tuberculosis. Cold Spring Harb Perspect Med (2014) 0.99
Risk of tuberculosis reactivation with tofacitinib (CP-690550). J Infect Dis (2012) 0.99
Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed Res Int (2013) 0.97
NF-κB Signaling Dynamics Play a Key Role in Infection Control in Tuberculosis. Front Physiol (2012) 0.96
Modeling tuberculosis in nonhuman primates. Cold Spring Harb Perspect Med (2014) 0.95
Stereological analysis of bacterial load and lung lesions in nonhuman primates (rhesus macaques) experimentally infected with Mycobacterium tuberculosis. Am J Physiol Lung Cell Mol Physiol (2011) 0.94
Mycobacterium tuberculosis requires phosphate-responsive gene regulation to resist host immunity. Infect Immun (2012) 0.93
A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques. Clin Vaccine Immunol (2012) 0.93
Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis. Dis Model Mech (2015) 0.93
The Mycobacterium tuberculosis PE proteins Rv0285 and Rv1386 modulate innate immunity and mediate bacillary survival in macrophages. PLoS One (2012) 0.93
PE11 (Rv1169c) selectively alters fatty acid components of Mycobacterium smegmatis and host cell interleukin-6 level accompanied with cell death. Front Microbiol (2015) 0.92
HIV and co-infections. Immunol Rev (2013) 0.92
Infections Caused by Mycobacterium tuberculosis in Recipients of Hematopoietic Stem Cell Transplantation. Front Oncol (2014) 0.91
Computational modeling predicts IL-10 control of lesion sterilization by balancing early host immunity-mediated antimicrobial responses with caseation during mycobacterium tuberculosis infection. J Immunol (2014) 0.91
Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine (2011) 0.91
Association of IFNGR2 gene polymorphisms with pulmonary tuberculosis among the Vietnamese. Hum Genet (2011) 0.91
Genome-wide transcriptional profiling of peripheral blood leukocytes from cattle infected with Mycobacterium bovis reveals suppression of host immune genes. BMC Genomics (2011) 0.90
O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection. PLoS Pathog (2013) 0.90
Spontaneous latency in a rabbit model of pulmonary tuberculosis. Am J Pathol (2012) 0.90
Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation disease. BMC Med (2015) 0.90
Mycobacterium tuberculosis Strains Are Differentially Recognized by TLRs with an Impact on the Immune Response. PLoS One (2013) 0.88
Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms. Expert Rev Anti Infect Ther (2012) 0.87
Circulating B-lymphocytes as potential biomarkers of tuberculosis infection activity. PLoS One (2014) 0.87
Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection. PLoS One (2011) 0.86
Deregulated microRNAs in CD4+ T cells from individuals with latent tuberculosis versus active tuberculosis. J Cell Mol Med (2013) 0.86
Key Hub and Bottleneck Genes Differentiate the Macrophage Response to Virulent and Attenuated Mycobacterium bovis. Front Immunol (2014) 0.86
18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med (2013) 0.86
Latent Tuberculosis: Models, Computational Efforts and the Pathogen's Regulatory Mechanisms during Dormancy. Front Bioeng Biotechnol (2013) 0.85
Validation of biomarkers for distinguishing Mycobacterium tuberculosis from non-tuberculous mycobacteria using gas chromatography-mass spectrometry and chemometrics. PLoS One (2013) 0.85
Immunomodulation by vitamin D: implications for TB. Expert Rev Clin Pharmacol (2011) 0.85
TB case detection: can we remain passive while the process is active? Pan Afr Med J (2012) 0.84
Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis (2016) 0.84
The impact of mucosal infections on acquisition and progression of tuberculosis. Mucosal Immunol (2011) 0.84
Nuclear imaging: a powerful novel approach for tuberculosis. Nucl Med Biol (2014) 0.84
Computational and Empirical Studies Predict Mycobacterium tuberculosis-Specific T Cells as a Biomarker for Infection Outcome. PLoS Comput Biol (2016) 0.83
Adequate Th2-type response associates with restricted bacterial growth in latent mycobacterial infection of zebrafish. PLoS Pathog (2014) 0.83
Serologic reactivity to the emerging pathogen Granulibacter bethesdensis. J Infect Dis (2012) 0.83
Identification of a major locus, TNF1, that controls BCG-triggered tumor necrosis factor production by leukocytes in an area hyperendemic for tuberculosis. Clin Infect Dis (2013) 0.83
New targets and inhibitors of mycobacterial sulfur metabolism. Infect Disord Drug Targets (2013) 0.83
PET CT Identifies Reactivation Risk in Cynomolgus Macaques with Latent M. tuberculosis. PLoS Pathog (2016) 0.83
PET/CT imaging of Mycobacterium tuberculosis infection. Clin Transl Imaging (2016) 0.82
Consensus Statement on Research Definitions for Drug-Resistant Tuberculosis in Children. J Pediatric Infect Dis Soc (2013) 0.82
Mycobacterium tuberculosis culture filtrate protein 10-specific effector/memory CD4⁺ and CD8⁺ T cells in tubercular pleural fluid, with biased usage of T cell receptor Vβ chains. Infect Immun (2011) 0.82
Two component systems: physiological effect of a third component. PLoS One (2012) 0.82
A multi-scale approach to designing therapeutics for tuberculosis. Integr Biol (Camb) (2015) 0.82
Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production. J Clin Microbiol (2014) 0.81
Tuberculosis vaccine types and timings. Clin Vaccine Immunol (2014) 0.81
Expression of proinflammatory and regulatory cytokines via NF-κB and MAPK-dependent and IFN regulatory factor-3-independent mechanisms in human primary monocytes infected by Mycobacterium tuberculosis. Clin Dev Immunol (2010) 0.81
A review of Vitamin D effects on common respiratory diseases: Asthma, chronic obstructive pulmonary disease, and tuberculosis. J Res Pharm Pract (2016) 0.80
Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC Infect Dis (2015) 0.80
Identification of a human immunodominant T-cell epitope of mycobacterium tuberculosis antigen PPE44. BMC Microbiol (2011) 0.80
Serological diagnosis of pulmonary Mycobacterium tuberculosis infection by LIPS using a multiple antigen mixture. BMC Microbiol (2015) 0.79
The Importance of First Impressions: Early Events in Mycobacterium tuberculosis Infection Influence Outcome. MBio (2016) 0.79
Exploratory study on plasma immunomodulator and antibody profiles in tuberculosis patients. Clin Vaccine Immunol (2013) 0.79
HIV Skews the Lineage-Defining Transcriptional Profile of Mycobacterium tuberculosis-Specific CD4+ T Cells. J Immunol (2016) 0.79
Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes. Clin Dev Immunol (2011) 0.78
Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment. Am J Pathol (2014) 0.78
Modeling Granulomas in Response to Infection in the Lung. PLoS One (2016) 0.78
Structure of Mycobacterium smegmatis Eis in complex with paromomycin. Acta Crystallogr F Struct Biol Commun (2014) 0.78
Tuberculosis in India--can we ensure a test, treatment & cure for all? Indian J Med Res (2014) 0.78
Association of Genetic Polymorphisms of IFNGR1 with the Risk of Pulmonary Tuberculosis in Zahedan, Southeast Iran. Tuberc Res Treat (2015) 0.78
Granuloma transplantation: an approach to study mycobacterium-host interactions. Front Microbiol (2011) 0.78
Interferon-gamma-dependent Immunity in Bacillus Calmette-Guérin Vaccine Osteitis Survivors. Pediatr Infect Dis J (2016) 0.77
Challenges and future in vaccines, drug development, and immunomodulatory therapy. Ann Am Thorac Soc (2014) 0.77
The immune response to tuberculosis infection in the setting of Helicobacter pylori and helminth infections. Epidemiol Infect (2012) 0.77
Experimental Reactivation of Pulmonary Mycobacterium avium Complex Infection in a Modified Cornell-Like Murine Model. PLoS One (2015) 0.77
Mycobacterial Dormancy Systems and Host Responses in Tuberculosis. Front Immunol (2017) 0.77
Mycobacterium tuberculosis infection interferes with HIV vaccination in mice. PLoS One (2012) 0.76
Toward Standardizing a Lexicon of Infectious Disease Modeling Terms. Front Public Health (2016) 0.76
Concomitant Immunity Induced by Persistent Leishmania major Does Not Preclude Secondary Re-Infection: Implications for Genetic Exchange, Diversity and Vaccination. PLoS Negl Trop Dis (2016) 0.76
Insufficient Generation of Mycobactericidal Mediators and Inadequate Level of Phagosomal Maturation Are Related with Susceptibility to Virulent Mycobacterium tuberculosis Infection in Mouse Macrophages. Front Microbiol (2016) 0.76
Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders. Lung (2014) 0.76
Dissemination of multidrug-resistant tuberculosis in a patient with acute HIV infection. BMC Infect Dis (2014) 0.75
TLR Agonist Augments Prophylactic Potential of Acid Inducible Antigen Rv3203 against Mycobacterium tuberculosis H37Rv in Experimental Animals. PLoS One (2016) 0.75
Mycobacterium tuberculosis multidrug resistant strain M induces an altered activation of cytotoxic CD8+ T cells. PLoS One (2014) 0.75
Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science (2006) 18.74
The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med (1994) 16.32
Immunology of tuberculosis. Annu Rev Immunol (2001) 14.26
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol (2007) 10.71
Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity (1995) 10.65
Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science (2006) 9.17
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol (2009) 8.13
Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A (1997) 7.90
Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol (2001) 6.92
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis (2007) 6.45
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med (2004) 5.90
Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med (1997) 5.48
IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol (2006) 5.27
An antimicrobial activity of cytolytic T cells mediated by granulysin. Science (1998) 5.02
Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med (2005) 4.72
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun (1995) 4.28
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis (1993) 4.01
The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog (2008) 3.79
Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med (2006) 3.54
Extrapulmonary tuberculosis in the United States. Am J Epidemiol (1979) 3.53
Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am J Respir Crit Care Med (2002) 3.50
TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med (2005) 3.44
Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun (2009) 3.31
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum (2006) 3.26
A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med (1999) 3.26
Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol (2010) 3.25
Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity (2008) 3.24
Patterns of tuberculosis transmission in Central Los Angeles. JAMA (1997) 3.21
Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med (2007) 3.21
Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis (2010) 3.21
Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis (2008) 3.15
Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med (2000) 2.97
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun (2001) 2.94
Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis (2002) 2.90
Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med (2007) 2.88
Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun (1997) 2.85
Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol (2002) 2.83
Effects of aminoguanidine on latent murine tuberculosis. J Immunol (1998) 2.83
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest (2007) 2.80
Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest (2004) 2.65
Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med (2008) 2.63
Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun (2006) 2.63
Transmission of tuberculosis in a high incidence urban community in South Africa. Int J Epidemiol (2004) 2.62
Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol (2000) 2.61
Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2001) 2.59
Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med (2008) 2.57
Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med (1992) 2.36
New measurable indicator for tuberculosis case detection. Emerg Infect Dis (2004) 2.34
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS (2005) 2.28
Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci U S A (2001) 2.21
Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol (2002) 2.17
Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol (2009) 2.16
Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One (2009) 2.14
Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One (2010) 2.14
Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest (2009) 2.12
A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog (2009) 2.09
CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol (2007) 2.08
Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum (2010) 2.05
Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet (2002) 1.98
Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis (2008) 1.94
Early emergence of CD8(+) T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice. Infect Immun (1999) 1.93
Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol (2001) 1.92
Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Infect Immun (2002) 1.89
MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect Immun (2004) 1.89
Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis (2005) 1.88
A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis (2006) 1.83
Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog (2008) 1.81
Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses. J Immunol (2005) 1.74
Mycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivo. J Immunol (2008) 1.73
Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol (2008) 1.67
Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet (2008) 1.65
Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2, -4 and -9. Eur J Immunol (2008) 1.59
Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J Infect Dis (2003) 1.58
Reduced Th17 response in patients with tuberculosis correlates with IL-6R expression on CD4+ T Cells. Am J Respir Crit Care Med (2009) 1.54
TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol (2004) 1.53
Role of CD8+ T lymphocytes in control of Mycobacterium tuberculosis infection. Microbes Infect (2005) 1.48
Mycobacterium tuberculosis-specific CD4+, IFNgamma+, and TNFalpha+ multifunctional memory T cells coexpress GM-CSF. Cytokine (2008) 1.46
Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinb) (2009) 1.45
Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum Genet (2009) 1.45
Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther (2006) 1.45
Quantitative scoring of an interferon-gamma assay for differentiating active from latent tuberculosis. Eur Respir J (2007) 1.45
IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One (2009) 1.43
Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis (2003) 1.41
Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis (2006) 1.39
Role of iNOS in human host defense. Science (2006) 1.35
Toll-like receptor 4-defective C3H/HeJ mice are not more susceptible than other C3H substrains to infection with Mycobacterium tuberculosis. Infect Immun (2003) 1.34
Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS One (2009) 1.33
Quantitative T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens in active and latent tuberculosis. Eur J Clin Microbiol Infect Dis (2008) 1.30
Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol (2005) 1.29
CD8+ T cells in tuberculosis. Am J Respir Crit Care Med (2002) 1.27
CD4(+) regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J Infect Dis (2010) 1.24
Transmission dynamics of tuberculosis in Tarrant county, Texas. Am J Respir Crit Care Med (2002) 1.22
Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun (2006) 2.63
Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One (2010) 2.14
HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun (2011) 2.03
Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol (2013) 1.62
Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunol (2006) 1.49
Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis (2007) 1.49
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A (2012) 1.48
IFN-γ from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J Immunol (2012) 1.47
New approaches to tuberculosis surveillance in nonhuman primates. ILAR J (2008) 1.35
Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother (2012) 1.32
CD4(+) regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J Infect Dis (2010) 1.24
Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun (2013) 1.16
B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog (2013) 1.14
Comparison of the effects of pathogenic simian human immunodeficiency virus strains SHIV-89.6P and SHIV-KU2 in cynomolgus macaques. AIDS Res Hum Retroviruses (2008) 1.01
Afferent and efferent interfaces of lymph nodes are distinguished by expression of lymphatic endothelial markers and chemokines. Lymphat Res Biol (2007) 0.93
The mutation rate of mycobacterial repetitive unit loci in strains of M. tuberculosis from cynomolgus macaque infection. BMC Genomics (2013) 0.90
The purinergic P2X7 receptor is not required for control of pulmonary Mycobacterium tuberculosis infection. Infect Immun (2005) 0.90
Alterations in T lymphocyte profiles of bronchoalveolar lavage fluid from SIV- and Pneumocystis carinii-coinfected rhesus macaques. AIDS Res Hum Retroviruses (2002) 0.89
New insights into mathematical modeling of the immune system. Immunol Res (2006) 0.83
Plasma antibody profiles in non-human primate tuberculosis. J Med Primatol (2014) 0.81